# A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers

> **NCT04931147** · PHASE1 · COMPLETED · sponsor: **Redx Pharma Ltd** · enrollment: 90 (actual)

## Conditions studied

- Fibrosis
- Inflammation
- Idiopathic Pulmonary Fibrosis
- Non-alcoholic Steatohepatitis
- Liver Diseases
- Kidney Diseases

## Interventions

- **DRUG:** RXC007
- **DRUG:** RXC007 Matching Placebo

## Key facts

- **NCT ID:** NCT04931147
- **Lead sponsor:** Redx Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-13
- **Primary completion:** 2023-03-08
- **Final completion:** 2023-03-08
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2023-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04931147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04931147, "A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04931147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*